Shots:
- The CHMP has recommended Tezspire for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP); regulatory review is ongoing in the US, China, Japan & other countries
- Opinion was based on the P-III (WAYPOINT) study assessing Tezspire (SC) vs PBO to treat adults with severe CRSwNP for 52wks., followed by a post-treatment follow-up duration of 12-24wks.
- Study met its co-1EPs, with a reduction in nasal polyp severity (per NPS) by -2.08 & a decrease in nasal congestion (per NCS) by -1.04 at 52wks., plus Tezspire reduced surgery needs by 98% & systemic corticosteroid use by 89%; results were presented at AAAAI/WAO’25 & published in The NEJM
Ref: AstraZeneca | Image: AstraZeneca and Amgen | Press Release
Related News:- AstraZeneca Reports Interim P-III (TULIP-SC) Trial Data of Saphnelo for Systemic Lupus Erythematosus (SLE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
